prodchem
Aug 21, 2026
Biotechnology company InduPro has raised $77 million in a Series B financing round, attracting simultaneous strategic investment from major pharmaceutical companies including Eli Lilly and Company, Sanofi, and Merck & Co. through MRL Ventures Fund.
The financing, announced on August 12, 2026, comes as InduPro moves its lead oncology program, IDP-001, into Phase 1 clinical development. The round was led by The Column Group and included existing investors Vida Ventures, MRL Ventures Fund, Emerson Collective, and Euclidean Capital, alongside new investors Solasta Ventures, Sanofi, and Eli Lilly.
The simultaneous participation of three major pharmaceutical organizations makes the financing particularly notable. It signals strong strategic interest in InduPro's approach to using protein proximity biology to discover new therapeutic targets and develop next-generation cancer and autoimmune treatments.
The Series B includes investment from venture and strategic arms connected to three major pharmaceutical companies:
Eli Lilly and Company
Sanofi
Merck & Co. through MRL Ventures Fund
MRL Ventures Fund is the therapeutics-focused venture arm of Merck. Both Sanofi and Lilly had already established strategic relationships with InduPro before participating in the Series B.
This makes the financing more than a conventional venture round. The participation of multiple pharmaceutical companies suggests that InduPro's underlying technology may have strategic value beyond its immediate lead program.
InduPro is developing therapeutics based on the spatial relationships between proteins located on cell surfaces.
Traditional drug discovery often focuses on whether a particular protein is present or absent on a diseased cell. InduPro's approach instead attempts to understand which proteins are located close to one another and whether those spatial relationships can be exploited therapeutically.
The company's proprietary platform maps protein neighborhoods on cell surfaces and uses those relationships to identify potential co-targets.
This approach could allow researchers to identify therapeutic opportunities that may be difficult to discover through conventional single-target screening.
The funding arrives at an important clinical milestone for InduPro.
The company has dosed the first patient in a Phase 1 study of IDP-001, its lead oncology program. The study is enrolling adults with advanced squamous and non-squamous non-small cell lung cancer and other solid tumors.
IDP-001 is a bispecific antibody-drug conjugate (ADC) designed to target EGFR together with a novel tumor-associated proximity antigen.
The objective is to use the spatial relationship between the two targets to improve tumor selectivity and therapeutic activity.
Moving the program into human testing represents a major transition for InduPro because clinical data will begin determining whether the company's proximity-based discovery approach can translate into meaningful therapeutic benefits.
The financing provides InduPro with capital to support several development priorities.
According to the company, proceeds will be used to:
Advance Phase 1 clinical development of IDP-001.
Generate early proof-of-concept clinical data.
Continue development of the broader preclinical pipeline.
Further develop the company's proximity-guided discovery platform.
The timing is significant because biotechnology companies typically require substantial capital as they transition from laboratory research into clinical development.
Clinical trials introduce additional costs related to manufacturing, regulatory activities, clinical sites, patient enrollment, data analysis, and long-term development.
The presence of major pharmaceutical investors can provide benefits beyond financing.
For an early-stage biotechnology company, strategic pharmaceutical investors can potentially contribute:
Scientific expertise.
Drug-development experience.
Regulatory knowledge.
Clinical-development capabilities.
Commercialization expertise.
Potential partnership opportunities.
Access to broader industry networks.
InduPro's existing relationships with Lilly and Sanofi demonstrate how venture investment can also exist alongside strategic collaboration.
Lilly entered into a collaboration with InduPro in January 2026 focused on developing bispecific and multispecific oncology therapeutics using InduPro's platform. The collaboration was reported as having a potential value of up to approximately $950 million. Sanofi had also established a collaboration with InduPro around an autoimmune-disease program.
This suggests that pharmaceutical companies may view InduPro's platform as potentially valuable across multiple therapeutic programs rather than only through ownership or investment.
InduPro's financing reflects a broader shift in biotechnology investment toward platform companies.
Rather than investing solely in one drug candidate, investors increasingly look for technologies that can generate multiple therapeutic programs.
A successful platform can potentially create several candidates using common discovery technologies, biological insights, data, and development capabilities.
This can make the underlying technology strategically valuable even when individual drug candidates remain at an early stage.
For pharmaceutical companies, investing early in such platforms can provide exposure to emerging technologies without requiring them to build every capability internally.
The financing also highlights continued investor interest in oncology biotechnology.
Cancer remains one of the most active areas of pharmaceutical research because of the significant unmet medical need and the possibility of developing targeted therapies for specific tumor types.
InduPro is attempting to address this opportunity through a different biological lens: rather than relying solely on conventional target expression, its technology considers spatial relationships between proteins on cancer cells.
The success of IDP-001 could therefore provide important validation for this approach.
However, the company remains at an early clinical stage, and the Phase 1 program will primarily provide information about safety, tolerability, pharmacokinetics, and early signals of clinical activity.
The simultaneous participation of Lilly, Sanofi, and Merck's venture arm can be interpreted as an indication that large pharmaceutical companies are actively evaluating new approaches to drug discovery.
For strategic investors, several questions are likely to matter:
A platform becomes particularly valuable if it can consistently uncover therapeutic targets that conventional approaches miss.
Scientific novelty alone is insufficient. The platform must generate candidates with favorable biological and pharmaceutical characteristics.
InduPro is developing programs in both oncology and autoimmune disease, potentially demonstrating broader applicability.
The long-term value of a platform depends on its ability to produce multiple viable therapeutic candidates.
The InduPro financing illustrates how the boundary between venture capital and pharmaceutical strategy is becoming increasingly interconnected.
Pharmaceutical companies are increasingly participating in early-stage biotechnology through corporate venture funds, strategic investments, licensing agreements, and collaborations.
For startups, this can provide access to capital while also creating relationships with potential future development or commercialization partners.
For pharmaceutical companies, these investments can provide early access to emerging technologies that may complement their internal research programs.
The InduPro transaction also offers an interesting signal for broader life sciences procurement and marketplace platforms.
As biotechnology companies develop increasingly specialized technologies, the supplier ecosystem around pharmaceutical research is becoming more complex.
Future procurement platforms may need to track not only conventional chemical suppliers but also:
Biotechnology companies.
Specialized research platforms.
Contract development and manufacturing organizations.
Novel biological materials.
Advanced analytical technologies.
Specialized laboratory services.
Regulatory and clinical-development partners.
For chemical and life sciences marketplaces, understanding investment and partnership activity can therefore provide an early indication of where future demand for specialized materials and technologies may emerge.
InduPro's $77 million Series B provides the company with substantial resources as its lead oncology program enters human testing.
More importantly, the simultaneous participation of Lilly, Sanofi, and Merck's MRL Ventures Fund demonstrates the strategic interest that large pharmaceutical organizations have in emerging proximity-based drug-discovery technologies.
The next major milestone will be the clinical performance of IDP-001 and the company's ability to demonstrate that its proximity-guided platform can repeatedly generate differentiated therapeutic candidates.
If clinical data validate the approach, InduPro could become an increasingly attractive partner for pharmaceutical companies seeking new mechanisms and platform technologies.
InduPro's $77 million Series B financing stands out not only because of its size but because of the unusual concentration of pharmaceutical strategic investors participating in the round.
With Eli Lilly, Sanofi, and Merck's MRL Ventures Fund all backing the company, the financing demonstrates growing pharmaceutical interest in proximity-based approaches to drug discovery.
The immediate focus is IDP-001, which has now entered Phase 1 testing for solid tumors. However, the larger strategic opportunity lies in InduPro's underlying platform and its potential to generate multiple therapeutic programs across oncology and autoimmune diseases.
For the biotechnology sector, the deal reinforces a broader trend: pharmaceutical companies are increasingly investing early in platform technologies that could shape the next generation of drug discovery rather than waiting until individual products reach late-stage development.
Featured Product
Found this useful?
Continue Reading
Heidi Overton’s nomination to lead the FDA comes after a turbulent period for the agency. Pharmaceutical companies and procurement teams are watching closely for shifts in drug review priorities, regulatory expectations and supply chain implications.
The growth of India's specialty ingredient trade show circuit, including the Chennai cosmetics event, reflects broader momentum in Indian specialty
The rubber industry is evaluating 6PPD replacement chemistry as environmental and performance priorities evolve. Cost, durability and proven tire protection remain central to procurement decisions.
